Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2014-07-04
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT02181699
- Locations
- 🇬🇧
University of Sussex, Royal Sussex County Hospital, Brighton, United Kingdom
🇬🇧Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇬🇧St James's Institute of Oncology, Leeds, United Kingdom
A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2014-06-30
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 41
- Registration Number
- NCT02177812
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
"InDACtion" vs "3+7" Induction in AML
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- Drug: standard combination chemotherapy
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2023-02-15
- Target Recruit Count
- 606
- Registration Number
- NCT02172872
- Locations
- 🇧🇪
UZ Antwerpen, Edegem, Antwerpen, Belgium
🇧🇪UZ Brussel, Jette, Brussels, Belgium
🇧🇪CHR Verviers, Verviers, Liège, Belgium
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)
- Conditions
- AML
- Interventions
- Biological: Flotetuzumab 3 ng/kg/day, 4 days on and 3 days offBiological: Flotetuzumab 10 ng/kg/day, 4 days on and 3 days offBiological: Flotetuzumab 30 ng/kg/day, 4 days on and 3 days offBiological: Flotetuzumab 100 ng/kg/day, 4 days on and 3 days offBiological: Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in doseBiological: Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in doseBiological: Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in doseBiological: Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in doseBiological: Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in doseBiological: Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 244
- Registration Number
- NCT02152956
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸UCSD Moores Cancer Center, La Jolla, California, United States
🇺🇸UCSF - Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Yoga Fatigue Study
- Conditions
- Acute Lymphocytic Leukemia in RelapseBurkitt's Lymphoma Stage IIIAcute Myeloid Leukemia (AML)Burkitt's Lymphoma Stage IVType 3 Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- The Hospital for Sick Children
- Target Recruit Count
- 125
- Registration Number
- NCT02134782
- Locations
- 🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇨🇦University of Calgary, Calgary, Alberta, Canada
🇨🇦The Hospital for Sick Children, Toronto, Ontario, Canada
Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2014-04-15
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Stemline Therapeutics, Inc.
- Target Recruit Count
- 138
- Registration Number
- NCT02113982
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸H. Lee Moffiitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML)
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 11
- Registration Number
- NCT02101983
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT02096042
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 19
- Registration Number
- NCT02089230
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Selinexor (KPT-330) in Older Patients With Relapsed AML
- Conditions
- Acute Myeloid Leukemia (AML)
- Interventions
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 317
- Registration Number
- NCT02088541
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center / University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Sutter Oncology & Hematology, Sacramento, California, United States
🇺🇸Stanford Cancer Institute / Stanford University, Stanford, California, United States